Regulus Therapeutics Inc. (RGLS)
-NasdaqGM 7.39 
0.05(0.68%) 4:00PM EDT
| Prev Close: | 7.34 |
|---|
| Open: | 7.35 |
|---|
| Bid: | 5.60 x 200 |
|---|
| Ask: | 7.39 x 100 |
|---|
| 1y Target Est: | 10.50 |
|---|
| Beta: | 2.042 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 7.25 - 7.47 |
|---|
| 52wk Range: | 4.02 - 7.89 |
|---|
| Volume: | 26,809 |
|---|
| Avg Vol (3m): | 56,171 |
|---|
| Market Cap: | 266.09M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.31 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IPOVIEW-Quiet U.S. biotech sector picks up steam in 2013at Reuters(Wed, May 22)
- Regulus to Present at Deutsche Bank 38th Annual Healthcare ConferencePR Newswire(Tue, May 21)
- REGULUS THERAPEUTICS INC. FinancialsEDGAR Online Financials(Tue, May 21)
- REGULUS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- Regulus Therapeutics CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, May 14)
- Regulus Provides Update on 'Road to the Clinic' Strategy and Reports First Quarter 2013 Financial Results and Recent HighlightsPR Newswire(Tue, May 14)
- Q1 2013 Regulus Therapeutics Earnings Release - After Market CloseCCBN(Tue, May 14)
- Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference CallPR Newswire(Tue, May 7)
- Regulus Therapeutics: Strong Balance Sheet As It Moves Into Clinical Developmentat Seeking Alpha(Mon, May 6)
- 3 Investment Ideas for Biotech Investorsat Motley Fool(Wed, May 1)
- Regulus to Present at 12th Annual Needham Healthcare ConferencePR Newswire(Wed, Apr 24)
- 3 Stocks Near 52-Week Highs Worth Sellingat Motley Fool(Thu, Apr 18)
- Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.PR Newswire(Mon, Apr 15)
- Why Regulus Therapeutics Is Poised to Keep Plungingat Motley Fool(Fri, Apr 5)
- Regulus Appoints William H. Rastetter, Ph.D. to its Board of DirectorsPR Newswire(Mon, Apr 1)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 20.99 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.59 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of microRNA therapeutics to treat a range of diseases primarily in the United States.
View More